妊娠生理药代动力学模型量化舍曲林母胎比值与羊水浓度
该研究在已发表的妊娠舍曲林PBPK模型中加入被动扩散及胎盘外排转运体P-gp和BCRP介导的清除,模拟40周孕龄下25–200 mg多种剂量,预测母婴血浆浓度并与五项临床研究的母血和脐带血实测值比较,模型预测准确性可接受。
要点
- 模型预测母体血浆Cmax、Cmin、Cavg的AFE分别为1.7、1.2、1.4。
- 脐带血相应AFE分别为1.2、1和1.1,脐带-母体比值AFE为0.7、0.9和0.8。
- 该PBPK模型或可指导妊娠期舍曲林剂量调整,兼顾母胎暴露。
核心结论
- 所建妊娠PBPK模型可预测舍曲林母体及胎儿暴露,或可指导妊娠期母体舍曲林剂量调整。
研究设计与样本
- 在已发表的妊娠舍曲林PBPK模型中加入被动扩散及胎盘外排转运体P-gp和BCRP介导的清除。
- 模拟40周孕龄下25–200 mg多种舍曲林剂量,预测母胎血浆Cmin、Cmax和Cavg。
- 以五项临床研究分娩时母血和脐带血实测浓度评价模型预测准确性。
主要发现
- 母体血浆舍曲林Cmax、Cmin、Cavg的平均折叠误差(AFE)分别为1.7、1.2和1.4。
- 脐带血舍曲林Cmax、Cmin、Cavg的AFE分别为1.2、1和1.1。
- 脐带-母体舍曲林浓度比值Cmax、Cmin、Cavg的AFE分别为0.7、0.9和0.8。
临床怎么用
- 可参考该模型预测的母胎暴露评估妊娠期舍曲林剂量调整,但需结合临床监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Selective serotonin reuptake inhibitors (SSRIs) are indicated for a variety of psychiatric conditions which may require treatment during pregnancy. Knowledge of appropriate SSRI dosages that maintain maternal therapeutic benefit and minimize fetal risk are needed. Assessment of fetal exposure to drugs is challenging since sampling is often limited to a single concentration from the umbilical cord at delivery. Physiologically based pharmacokinetic (PBPK) modelling provides a non-invasive approach to quantify exposure in pregnancy. METHODS: We incorporated sertraline clearances mediated by passive diffusion, placental efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) into our previously published pregnancy PBPK model for sertraline. Simulations were performed for various sertraline doses (25-200 mg) at 40 weeks gestational age to predict the minimum (Cmin), maximum (Cmax) and average (Cavg) sertraline maternal and fetal plasma concentrations and evaluated them against observed maternal and cord concentrations obtained at delivery from five clinical studies. RESULTS: The accuracy of the PBPK predictions as indicated by the average fold error (AFE) value for Cmax, Cmin and Cavg for maternal plasma sertraline concentrations at delivery was 1.7, 1.2 and 1.4, respectively. The AFE for the Cmax, Cmin and Cavg for cord blood sertraline concentration at delivery was 1.2, 1 and 1.1, respectively. The AFE for cord-maternal sertraline concentration ratio at delivery for Cmax, Cmin and Cavg was 0.7, 0.9 and 0.8, respectively. CONCLUSIONS: The PBPK model we developed may serve as a guide for maternal sertraline dose adjustment during pregnancy considering changes in exposures for both mother and fetus.
引用
- Lartey D, Jateng D, Li M, et al. Quantification of sertraline maternal/fetal ratio and amniotic fluid concentration using a pregnancy physiologically based pharmacokinetic model. Br J Clin Pharmacol. 2023. PMID: 37312614. doi:10.1111/bcp.15826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。